luvox weight loss reviews_6

luvox weight loss reviews_6 luvox cr weight loss Hepatic Enzymes: Treatment with fluvoxamine has been rarely associated with increases in hepatic enzymes, usually apanied by symptoms. Fluvoxamine administration should be discontinued in such cases.bination with Alcohol: Fluvoxamine may potentiate the effects of alcohol and increase the level of psychomotor impairment. Occupational Hazards: Sedation may occur in some patients. Therefore, patients should be cautioned about participating in activities requiringplete mental alertness, judgment and physical coordination - such as driving an automobile or performing hazardous tasks - until they are reasonably certain that treatment with fluvoxamine does not affect them adversely. Suicide: The possibility of a suicide attempt is inherent in depression and may persist until significant remission occurs. Therefore, high-risk patients should be closely supervised throughout therapy and consideration should be given to the possible need for hospitalization. In order to minimize the opportunity for overdosage, prescriptions for fluvoxamine should be written for the smallest quantity of drug consistent with good patient management. Coitant Illness: Fluvoxamine has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were systematically excluded from premarketing clinical studies. Pregnancy and Lactation: Safe use of fluvoxamine during pregnancy and lactation has not been established. Therefore, it should not be administered to women of childbearing potential or nursing mothers unless, in the opinion of the treating physician, the expected benefits to the patient outweigh the possible hazards to the child or fetus. Children: Safety and efficacy in children under 18 years of age have not been established. Drug Interactions:bined use of fluvoxamine and MAO inhibitors is contraindicated see Contraindications. An increase in tricyclic antidepressant blood levels has also been reported in patients taking fluvoxamine coitantly. Lithium, and possibly tryptophan, may enhance the serotonergic effects of fluvoxamine; thesebinations should therefore be used with caution. Fluvoxamine may prolong the elimination of drugs which are metabolized by oxidation in the liver, and a clinically significant interaction is more likely when the second agent has a narrow therapeutic index, as is the case with warfarin, phenytoin and theophylline. Suchbinations should therefore be administered with caution, and consideration be given to lowering the dose of the second agent. In interaction studies, a 5-fold increase in plasma levels of propranolol and a 65% increase in warfarin plasma levels were seen during concurrent administration of fluvoxamine. An absence of pharmacokinetic interaction has been seen with digoxin and atenolol, which are not significantly metabolized in the liver. Cytochrome P450 Isozyme IID6: Like other selective serotonin reuptake inhibitors, fluvoxamine inhibits the specific hepatic cytochrome P450 isozyme IID6 which is responsible for the metabolism of debrisoquine and sparteine. Although the clinical significance of this effect has not been established, inhibition of IID6 may lead to elevated plasma levels of co-administered drugs which are metabolized by this isozyme. Drugs metabolized by cytochrome P450IID6 include the tricyclic antidepressants e.g. nortriptyline, amitriptyline, imipramine, and desipramine, phenothiazine neuroleptics e.g. perphenazine and thioridazine, and Type 1C antiarrhythmics e.g. propafenone and flecainide. Adverse Effectsmonly Observed: In clinical trials, the mostmonly observed adverse events associated with fluvoxamine administration, and not seen at an equivalent incidence among placebo-treated patients, were gastrointestinalplaints, including nausea sometimes apanied by vomiting, constipation, anorexia, diarrhea and dyspepsia; CNSplaints, including somnolence, dry mouth, nervousness, insomnia, dizziness, tremor and agitation; and asthenia. Abnormal mostly delayed ejaculation was frequently reported by patients with obsessivepulsive disorder, primarily at doses over 150 mg/day. Adverse Events Leading to Discontinuation of Treatment: Fifteen percent of approximately 25000 patients who received fluvoxamine in clinical trials discontinued treatment due to an adverse event. The moremon events causing discontinuation from depression trials included nausea and vomiting, insomnia, agitation, headache, abdominal pain, somnolence, dizziness, asthenia and anorexia. The mostmon events causing discontinuation in patients suffering from obsessivepulsive disorder included insomnia, asthenia and somnolence. Incidence of Adverse Experiences: Adverse events with an incidence of >= 5% reported in double-blind, placebo-controlled clinical trials in depression and in obsessivepulsive disorder are presented in table I for each indication. -------------------------------------------------------------------------- Table I Treatment - Emergent Adverse Experience Incidence >= 5% in Placebo-Controlled Clinical Trials for Depression and Obsessivepulsive Disorder* -------------------------------------------------------------------------- Percentage of Patients Reporting Event Depression OCD Body System/ Fluvoxamine Placebo Fluvoxamine Placebo Adverse Event N=222 N=192 N=160 N=160 ---------------------------------------------------------------------- Nervous System Somnolence 26.2 9.0 26.9 9.4 Agitation 15.7 8.9 3.8 0 Insomnia 14.4 10.4 31.3 15.0 Dizziness 14.8 13.5 9.4 4.4 Tremor 10.8 4.7 8.1 0.6 Hypokinesia 8.1 3.6 - - Hyperkinesia 6.7 8.9 - - Depression 4.0 4.2 6.3 4.4 Nervousness 2.2 1.6 15.6 5.0 Anxiety 2.3 2.1 9.4 6.9 Libido decreased - - 7.5 1.9 Thinking abnormal - - 6.9 3.8 Digestive System Nausea 36.5 10.9 28.8 6.9 Dry mouth 25.7 23.9 11.9 3.1 Constipation 18.0 6.8 14.4 8.8 Anorexia 14.9 6.3 5.0 3.1 Diarrhea 5.9 6.3 11.9 8.8 Dyspepsia 3.2 0 13.8 9.4 Body as a Whole Headache 21.6 18.7 20.0 23.8 Pain 5.9 3.7 4.4 1.3 Asthenia 4.9 3.2 28.8 9.4 Infection - - 11.3 9.4 Abdominal pain 3.6 3.6 5.6 8.1 Flu syndrome - - 5.0 3.8 Skin Sweating increased 11.2 12.5 6.9 1.9 Respiratory System Pharyngitis - - 6.3 5.0 Rhinitis 1.3 2.6 5.6 1.9 Special Senses Amodation abnormal 6.3 6.3 - - Taste perversion 3.2 3.1 5.0 0 Urogenital Urinary frequency 2.2 1.6 5.0 1.3 Abnormal ejaculation 1.4 0 17.9+ 0 --------------------------------------------------------------------- *Dosage titration at study initiation varied between the depression an d OCD trials. In depression, fluvoxamine was administered: Day 1, 50 mg hs; Day 2, 100 mg; Day 3, 150 mg then titrated to response. In OCD, fluvoxamine was administered: Days 1 to 4, 50 mg; Days 5 to 8, 100 mg, Days 9 to 14, 150 mg then titrated to response. +Corrected for gender males: n=78. --------------------------------------------------------------------- During premarketing and postmarketing studies, multiple doses of fluvoxamine were administered to approximately 25000 patients. All events with an incidence of > 0.01% are listed, regardless of relation to drug, except those in terms so general as to be uninformative. Events are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: Frequent occurring on 1 or more occasions in at least 1% of patients, infrequent occurring in less than 1%, but at least 0.1% of patients, or rare occurring in less than 0.1% but at least in 0.01% of patients. Multiple events may have been reported by a single patient. It is important to emphasize that although the events reported did occur during treatment with fluvoxamine, they were not necessarily caused by it. Nervous System: Frequent: Somnolence, dry mouth, insomnia, dizziness, nervousness, tremor, vertigo, thinking abnormal, agitation, anxiety, amnesia, depression. Infrequent: Abnormal dreams, paresthesia, vasodilatation, libido decreased, depersonalization, psychotic depression, hypertonia, confusion, apathy, emotional lability, ataxia, abnormal gait, hostility, hyperkinesia, libido increased, hypokinesia, euphoria, neurosis, incoordination, hypesthesia, increased salivation. Rare: Screaming syndrome, hypotonia, hemiplegia, hallucinations, akathisia, manic reaction, myoclonus, twitching, drug dependence, stupor, delirium, convulsion, neuralgia, dysarthria, paranoid reaction, extrapyramidal syndrome, neuropathy, CNS neoplasia, akinesia, dyskinesia, paralysis, psychosis, CNS stimulation,a, delusions, hyperesthesia, hysteria, schizophrenic reaction, torticollis, trismus, dystonia, reflexes decreased. Digestive: Frequent: Nausea, vomiting, dyspepsia, constipation, diarrhea, anorexia. Infrequent: Flatulence, dysphagia, increased appetite, eructation, thirst, colitis. Rare: Gastroenteritis, gastritis, stomatitis, glossitis, hepatitis, esophagitis, fecal incontinence, gingivitis, jaundice, mouth ulceration, rectal hemorrhage, melena, tongue discoloration, tooth disorder, biliary pain, gastrointestinal carcinoma, gastrointestinal hemorrhage, hematemesis, liver function tests abnormal, tenesmus, tongue edema. Cardiovascular: Frequent: Palpitation. Infrequent: Syncope, tachycardia, postural hypotension, hypotension, migraine, hypertension. Rare: Angina pectoris, arrhythmia, myocardial infarct, pallor, bradycardia, extrasystoles, hemorrhage, peripheral vascular disorder, cerebrovascular accident, shock. Body as a Whole: Frequent: Asthenia, headache, abdominal pain, malaise, pain. Infrequent: Back pain, chills, chest pain, suicide attempt, fever, neck pain, infection, allergic reaction, accidental injury, flu syndrome. Rare: Overdose, face edema, hangover effect, abdomen enlarged, halitosis, neck rigidity, pelvic pain, hernia, chills and fever. Skin: Frequent: Sweating increased. Infrequent: Pruritus, rash. Rare: Urticaria, acne, eczema, dry skin, alopecia, psoriasis, furunculosis, Herpes simplex, Herpes zoster, maculopapular rash. Respiratory: Infrequent: Dyspnea, pharyngitis, rhinitis. Rare: Cough increased, yawn, epistaxis, hyperventilation, sinusitis, bronchitis, laryngismus, hiccup, pneumonia, asthma, laryngitis, voice alternation. Special Senses: Infrequent: Taste perversion, tinnitus, amblyopia, abnormal vision, hyperacusis. Rare: Conjunctivitis, abnormality of amodation, taste loss, eye pain, lacrimation disorder, diplopia, dry eyes, mydriasis, ear pain, parosmia, deafness, photophobia, blepharitis. Musculoskeletal: Infrequent: Myalgia, arthralgia, myasthenia, tetany. Rare: Leg cramps, arthrosis, rheumatoid arthritis, arthritis, bone pain, pathological fracture. Urogenital: Infrequent: Urinary frequency, impotence, dysuria, metrorrhagia, abnormal ejaculation. Rare: Urinary incontinence, breast pain, urinary retention, urinary urgency, cystitis, nocturia, menorrhagia, anorgasmia, female lactation, vaginitis, amenorrhea, dysmenorrhea, urinary tract infection, hematuria, kidney pain, prostatic disorder, polyuria, leukorrhea. Metabolic and Nutritional: Frequent: Weight gain. Infrequent: Weight loss, peripheral edema. Rare: Alcohol intolerance, dehydration, obesity, edema. Hematic and Lymph: Rare: Ecchymosis, cyanosis, anemia, lymphadenopathy, thrombocytopenia. Overdose Symptoms: More than 300 cases of overdosage with fluvoxamine, alone or inbination with otherpounds, have been reported. The mostmon symptoms of overdosage include gastrointestinalplaints nausea, vomiting and diarrhea, somnolence and dizziness. Cardiac events tachycardia, bradycardia, hypotension, liver function disturbances, convulsions anda have also been reported. Among 300 patients reported to have taken deliberate overdoses of fluvoxamine, there have been 15 deaths, all but one of which occurred in patients who were confirmed to have taken multiple medications. Treatment: There is no specific antidote to fluvoxamine. In situations of overdosage, the stomach should be emptied as soon as possible after tablet ingestion and symptomatic treatment initiated. The repeated use of medicinal charcoal is also rmended. Due to the large distribution volume of fluvoxamine, forced diuresis or dialysis is unlikely to be of benefit. The highest documented dose of fluvoxamine ingested by a patient is 9000 mg; this patient recoveredpletely with symptomatic treatment only. Dosage Depression: Adult Dosage: Treatment should be initiated at the lowest possible dose 50 mg given once daily at bedtime, and then increased to 100 mg daily at bedtime after a few days, as tolerated. The effective daily dose usually lies between 100 and 200 mg, and should be adjusted gradually according to the individual response of the patient, up to a maximum of 300 mg. Dosage increases should be made in 50 mg increments. Doses above 150 mg should be divided so that a maximum of 150 mg is given in the bedtime dose. Tablets should be swallowed with water and without chewing. Obsessivepulsive Disorder: Adult Dosage: Treatment should be initiated at the lowest possible dose 50 mg given once daily at bedtime, and then increased to 100 mg daily at bedtime after a few days, as tolerated. The effective daily dose usually lies between 100 and 300 mg, and should be adjusted gradually according to the individual response of the patient, up to a maximum of 300 mg. If no improvement is observed within 10 weeks, treatment with fluvoxamine should be reconsidered. Dosage increases should be made in 50 mg increments. Doses above 150 mg should be divided so that a maximum of 150 mg is given in the bedtime dose. Fluvoxamine should be swallowed with water and without chewing. Hepatic or Renal Insufficiency: Patients with hepatic or renal insufficiency should begin treatment with a low dose and be carefully monitored. Children: The safety and effectiveness of fluvoxamine in children under 18 years of age have not been established. Geriatrics: Since there is limited clinical experience in the geriatric age group, caution is rmended when administering fluvoxamine to elderly patients.

luvox weight loss reviews_6 And Medical History :Hepatic Enzymes: Treatment with fluvoxamine has been rarely associated with increases in hepatic enzymes, usually apanied by symptoms. Fluvoxamine administration should be discontinued in such cases.bination with Alcohol: Fluvoxamine may potentiate the effects of alcohol and increase the level of psychomotor impairment. Occupational Hazards: Sedation may occur in some patients. Therefore, patients should be cautioned about participating in activities requiringplete mental alertness, judgment and physical coordination - such as driving an automobile or performing hazardous tasks - until they are reasonably certain that treatment with fluvoxamine does not affect them adversely. Suicide: The possibility of a suicide attempt is inherent in depression and may persist until significant remission occurs. Therefore, high-risk patients should be closely supervised throughout therapy and consideration should be given to the possible need for hospitalization. In order to minimize the opportunity for overdosage, prescriptions for fluvoxamine should be written for the smallest quantity of drug consistent with good patient management. Coitant Illness: Fluvoxamine has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were systematically excluded from premarketing clinical studies. Pregnancy and Lactation: Safe use of fluvoxamine during pregnancy and lactation has not been established. Therefore, it should not be administered to women of childbearing potential or nursing mothers unless, in the opinion of the treating physician, the expected benefits to the patient outweigh the possible hazards to the child or fetus. Children: Safety and efficacy in children under 18 years of age have not been established. Drug Interactions:bined use of fluvoxamine and MAO inhibitors is contraindicated see Contraindications. An increase in tricyclic antidepressant blood levels has also been reported in patients taking fluvoxamine coitantly. Lithium, and possibly tryptophan, may enhance the serotonergic effects of fluvoxamine; thesebinations should therefore be used with caution. Fluvoxamine may prolong the elimination of drugs which are metabolized by oxidation in the liver, and a clinically significant interaction is more likely when the second agent has a narrow therapeutic index, as is the case with warfarin, phenytoin and theophylline. Suchbinations should therefore be administered with caution, and consideration be given to lowering the dose of the second agent. In interaction studies, a 5-fold increase in plasma levels of propranolol and a 65% increase in warfarin plasma levels were seen during concurrent administration of fluvoxamine. An absence of pharmacokinetic interaction has been seen with digoxin and atenolol, which are not significantly metabolized in the liver. Cytochrome P450 Isozyme IID6: Like other selective serotonin reuptake inhibitors, fluvoxamine inhibits the specific hepatic cytochrome P450 isozyme IID6 which is responsible for the metabolism of debrisoquine and sparteine. Although the clinical significance of this effect has not been established, inhibition of IID6 may lead to elevated plasma levels of co-administered drugs which are metabolized by this isozyme. Drugs metabolized by cytochrome P450IID6 include the tricyclic antidepressants e.g. nortriptyline, amitriptyline, imipramine, and desipramine, phenothiazine neuroleptics e.g. perphenazine and thioridazine, and Type 1C antiarrhythmics e.g. propafenone and flecainide. Adverse Effectsmonly Observed: In clinical trials, the mostmonly observed adverse events associated with fluvoxamine administration, and not seen at an equivalent incidence among placebo-treated patients, were gastrointestinalplaints, including nausea sometimes apanied by vomiting, constipation, anorexia, diarrhea and dyspepsia; CNSplaints, including somnolence, dry mouth, nervousness, insomnia, dizziness, tremor and agitation; and asthenia. Abnormal mostly delayed ejaculation was frequently reported by patients with obsessivepulsive disorder, primarily at doses over 150 mg/day. Adverse Events Leading to Discontinuation of Treatment: Fifteen percent of approximately 25000 patients who received fluvoxamine in clinical trials discontinued treatment due to an adverse event. The moremon events causing discontinuation from depression trials included nausea and vomiting, insomnia, agitation, headache, abdominal pain, somnolence, dizziness, asthenia and anorexia. The mostmon events causing discontinuation in patients suffering from obsessivepulsive disorder included insomnia, asthenia and somnolence. Incidence of Adverse Experiences: Adverse events with an incidence of >= 5% reported in double-blind, placebo-controlled clinical trials in depression and in obsessivepulsive disorder are presented in table I for each indication. -------------------------------------------------------------------------- Table I Treatment - Emergent Adverse Experience Incidence >= 5% in Placebo-Controlled Clinical Trials for Depression and Obsessivepulsive Disorder* -------------------------------------------------------------------------- Percentage of Patients Reporting Event Depression OCD Body System/ Fluvoxamine Placebo Fluvoxamine Placebo Adverse Event N=222 N=192 N=160 N=160 ---------------------------------------------------------------------- Nervous System Somnolence 26.2 9.0 26.9 9.4 Agitation 15.7 8.9 3.8 0 Insomnia 14.4 10.4 31.3 15.0 Dizziness 14.8 13.5 9.4 4.4 Tremor 10.8 4.7 8.1 0.6 Hypokinesia 8.1 3.6 - - Hyperkinesia 6.7 8.9 - - Depression 4.0 4.2 6.3 4.4 Nervousness 2.2 1.6 15.6 5.0 Anxiety 2.3 2.1 9.4 6.9 Libido decreased - - 7.5 1.9 Thinking abnormal - - 6.9 3.8 Digestive System Nausea 36.5 10.9 28.8 6.9 Dry mouth 25.7 23.9 11.9 3.1 Constipation 18.0 6.8 14.4 8.8 Anorexia 14.9 6.3 5.0 3.1 Diarrhea 5.9 6.3 11.9 8.8 Dyspepsia 3.2 0 13.8 9.4 Body as a Whole Headache 21.6 18.7 20.0 23.8 Pain 5.9 3.7 4.4 1.3 Asthenia 4.9 3.2 28.8 9.4 Infection - - 11.3 9.4 Abdominal pain 3.6 3.6 5.6 8.1 Flu syndrome - - 5.0 3.8 Skin Sweating increased 11.2 12.5 6.9 1.9 Respiratory System Pharyngitis - - 6.3 5.0 Rhinitis 1.3 2.6 5.6 1.9 Special Senses Amodation abnormal 6.3 6.3 - - Taste perversion 3.2 3.1 5.0 0 Urogenital Urinary frequency 2.2 1.6 5.0 1.3 Abnormal ejaculation 1.4 0 17.9+ 0 --------------------------------------------------------------------- *Dosage titration at study initiation varied between the depression an d OCD trials. In depression, fluvoxamine was administered: Day 1, 50 mg hs; Day 2, 100 mg; Day 3, 150 mg then titrated to response. In OCD, fluvoxamine was administered: Days 1 to 4, 50 mg; Days 5 to 8, 100 mg, Days 9 to 14, 150 mg then titrated to response. +Corrected for gender males: n=78. --------------------------------------------------------------------- During premarketing and postmarketing studies, multiple doses of fluvoxamine were administered to approximately 25000 patients. All events with an incidence of > 0.01% are listed, regardless of relation to drug, except those in terms so general as to be uninformative. Events are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: Frequent occurring on 1 or more occasions in at least 1% of patients, infrequent occurring in less than 1%, but at least 0.1% of patients, or rare occurring in less than 0.1% but at least in 0.01% of patients. Multiple events may have been reported by a single patient. It is important to emphasize that although the events reported did occur during treatment with fluvoxamine, they were not necessarily caused by it. Nervous System: Frequent: Somnolence, dry mouth, insomnia, dizziness, nervousness, tremor, vertigo, thinking abnormal, agitation, anxiety, amnesia, depression. Infrequent: Abnormal dreams, paresthesia, vasodilatation, libido decreased, depersonalization, psychotic depression, hypertonia, confusion, apathy, emotional lability, ataxia, abnormal gait, hostility, hyperkinesia, libido increased, hypokinesia, euphoria, neurosis, incoordination, hypesthesia, increased salivation. Rare: Screaming syndrome, hypotonia, hemiplegia, hallucinations, akathisia, manic reaction, myoclonus, twitching, drug dependence, stupor, delirium, convulsion, neuralgia, dysarthria, paranoid reaction, extrapyramidal syndrome, neuropathy, CNS neoplasia, akinesia, dyskinesia, paralysis, psychosis, CNS stimulation,a, delusions, hyperesthesia, hysteria, schizophrenic reaction, torticollis, trismus, dystonia, reflexes decreased. Digestive: Frequent: Nausea, vomiting, dyspepsia, constipation, diarrhea, anorexia. Infrequent: Flatulence, dysphagia, increased appetite, eructation, thirst, colitis. Rare: Gastroenteritis, gastritis, stomatitis, glossitis, hepatitis, esophagitis, fecal incontinence, gingivitis, jaundice, mouth ulceration, rectal hemorrhage, melena, tongue discoloration, tooth disorder, biliary pain, gastrointestinal carcinoma, gastrointestinal hemorrhage, hematemesis, liver function tests abnormal, tenesmus, tongue edema. Cardiovascular: Frequent: Palpitation. Infrequent: Syncope, tachycardia, postural hypotension, hypotension, migraine, hypertension. Rare: Angina pectoris, arrhythmia, myocardial infarct, pallor, bradycardia, extrasystoles, hemorrhage, peripheral vascular disorder, cerebrovascular accident, shock. Body as a Whole: Frequent: Asthenia, headache, abdominal pain, malaise, pain. Infrequent: Back pain, chills, chest pain, suicide attempt, fever, neck pain, infection, allergic reaction, accidental injury, flu syndrome. Rare: Overdose, face edema, hangover effect, abdomen enlarged, halitosis, neck rigidity, pelvic pain, hernia, chills and fever. Skin: Frequent: Sweating increased. Infrequent: Pruritus, rash. Rare: Urticaria, acne, eczema, dry skin, alopecia, psoriasis, furunculosis, Herpes simplex, Herpes zoster, maculopapular rash. Respiratory: Infrequent: Dyspnea, pharyngitis, rhinitis. Rare: Cough increased, yawn, epistaxis, hyperventilation, sinusitis, bronchitis, laryngismus, hiccup, pneumonia, asthma, laryngitis, voice alternation. Special Senses: Infrequent: Taste perversion, tinnitus, amblyopia, abnormal vision, hyperacusis. Rare: Conjunctivitis, abnormality of amodation, taste loss, eye pain, lacrimation disorder, diplopia, dry eyes, mydriasis, ear pain, parosmia, deafness, photophobia, blepharitis. Musculoskeletal: Infrequent: Myalgia, arthralgia, myasthenia, tetany. Rare: Leg cramps, arthrosis, rheumatoid arthritis, arthritis, bone pain, pathological fracture. Urogenital: Infrequent: Urinary frequency, impotence, dysuria, metrorrhagia, abnormal ejaculation. Rare: Urinary incontinence, breast pain, urinary retention, urinary urgency, cystitis, nocturia, menorrhagia, anorgasmia, female lactation, vaginitis, amenorrhea, dysmenorrhea, urinary tract infection, hematuria, kidney pain, prostatic disorder, polyuria, leukorrhea. Metabolic and Nutritional: Frequent: Weight gain. Infrequent: Weight loss, peripheral edema. Rare: Alcohol intolerance, dehydration, obesity, edema. Hematic and Lymph: Rare: Ecchymosis, cyanosis, anemia, lymphadenopathy, thrombocytopenia. Overdose Symptoms: More than 300 cases of overdosage with fluvoxamine, alone or inbination with otherpounds, have been reported. The mostmon symptoms of overdosage include gastrointestinalplaints nausea, vomiting and diarrhea, somnolence and dizziness. Cardiac events tachycardia, bradycardia, hypotension, liver function disturbances, convulsions anda have also been reported. Among 300 patients reported to have taken deliberate overdoses of fluvoxamine, there have been 15 deaths, all but one of which occurred in patients who were confirmed to have taken multiple medications. Treatment: There is no specific antidote to fluvoxamine. In situations of overdosage, the stomach should be emptied as soon as possible after tablet ingestion and symptomatic treatment initiated. The repeated use of medicinal charcoal is also rmended. Due to the large distribution volume of fluvoxamine, forced diuresis or dialysis is unlikely to be of benefit. The highest documented dose of fluvoxamine ingested by a patient is 9000 mg; this patient recoveredpletely with symptomatic treatment only. Dosage Depression: Adult Dosage: Treatment should be initiated at the lowest possible dose 50 mg given once daily at bedtime, and then increased to 100 mg daily at bedtime after a few days, as tolerated. The effective daily dose usually lies between 100 and 200 mg, and should be adjusted gradually according to the individual response of the patient, up to a maximum of 300 mg. Dosage increases should be made in 50 mg increments. Doses above 150 mg should be divided so that a maximum of 150 mg is given in the bedtime dose. Tablets should be swallowed with water and without chewing. Obsessivepulsive Disorder: Adult Dosage: Treatment should be initiated at the lowest possible dose 50 mg given once daily at bedtime, and then increased to 100 mg daily at bedtime after a few days, as tolerated. The effective daily dose usually lies between 100 and 300 mg, and should be adjusted gradually according to the individual response of the patient, up to a maximum of 300 mg. If no improvement is observed within 10 weeks, treatment with fluvoxamine should be reconsidered. Dosage increases should be made in 50 mg increments. Doses above 150 mg should be divided so that a maximum of 150 mg is given in the bedtime dose. Fluvoxamine should be swallowed with water and without chewing. Hepatic or Renal Insufficiency: Patients with hepatic or renal insufficiency should begin treatment with a low dose and be carefully monitored. Children: The safety and effectiveness of fluvoxamine in children under 18 years of age have not been established. Geriatrics: Since there is limited clinical experience in the geriatric age group, caution is rmended when administering fluvoxamine to elderly patients. The medical history of the patient is very important before luvox weight loss reviews_6 treatment can begin. The doctor needs to establish whether one has undergone a medical procedure such as surgery. luvox weight loss reviews_6 is effective for the indication it is meant for but it lower the body`s ability to fight infection. When one is recuperating from a surgery, using luvox weight loss reviews_6 can create a chance for infections to affect the body. It is advisable for a patient that is using luvox weight loss reviews_6 to stay indoors. Over crowded places can expose one to infections as well. Doctors say that during luvox weight loss reviews_6 treatment, the body is very weak and therefore vulnerable to contagious diseases.

Hepatic Enzymes: Treatment with fluvoxamine has been rarely associated with increases in hepatic enzymes, usually apanied by symptoms. Fluvoxamine administration should be discontinued in such cases.bination with Alcohol: Fluvoxamine may potentiate the effects of alcohol and increase the level of psychomotor impairment. Occupational Hazards: Sedation may occur in some patients. Therefore, patients should be cautioned about participating in activities requiringplete mental alertness, judgment and physical coordination - such as driving an automobile or performing hazardous tasks - until they are reasonably certain that treatment with fluvoxamine does not affect them adversely. Suicide: The possibility of a suicide attempt is inherent in depression and may persist until significant remission occurs. Therefore, high-risk patients should be closely supervised throughout therapy and consideration should be given to the possible need for hospitalization. In order to minimize the opportunity for overdosage, prescriptions for fluvoxamine should be written for the smallest quantity of drug consistent with good patient management. Coitant Illness: Fluvoxamine has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were systematically excluded from premarketing clinical studies. Pregnancy and Lactation: Safe use of fluvoxamine during pregnancy and lactation has not been established. Therefore, it should not be administered to women of childbearing potential or nursing mothers unless, in the opinion of the treating physician, the expected benefits to the patient outweigh the possible hazards to the child or fetus. Children: Safety and efficacy in children under 18 years of age have not been established. Drug Interactions:bined use of fluvoxamine and MAO inhibitors is contraindicated see Contraindications. An increase in tricyclic antidepressant blood levels has also been reported in patients taking fluvoxamine coitantly. Lithium, and possibly tryptophan, may enhance the serotonergic effects of fluvoxamine; thesebinations should therefore be used with caution. Fluvoxamine may prolong the elimination of drugs which are metabolized by oxidation in the liver, and a clinically significant interaction is more likely when the second agent has a narrow therapeutic index, as is the case with warfarin, phenytoin and theophylline. Suchbinations should therefore be administered with caution, and consideration be given to lowering the dose of the second agent. In interaction studies, a 5-fold increase in plasma levels of propranolol and a 65% increase in warfarin plasma levels were seen during concurrent administration of fluvoxamine. An absence of pharmacokinetic interaction has been seen with digoxin and atenolol, which are not significantly metabolized in the liver. Cytochrome P450 Isozyme IID6: Like other selective serotonin reuptake inhibitors, fluvoxamine inhibits the specific hepatic cytochrome P450 isozyme IID6 which is responsible for the metabolism of debrisoquine and sparteine. Although the clinical significance of this effect has not been established, inhibition of IID6 may lead to elevated plasma levels of co-administered drugs which are metabolized by this isozyme. Drugs metabolized by cytochrome P450IID6 include the tricyclic antidepressants e.g. nortriptyline, amitriptyline, imipramine, and desipramine, phenothiazine neuroleptics e.g. perphenazine and thioridazine, and Type 1C antiarrhythmics e.g. propafenone and flecainide. Adverse Effectsmonly Observed: In clinical trials, the mostmonly observed adverse events associated with fluvoxamine administration, and not seen at an equivalent incidence among placebo-treated patients, were gastrointestinalplaints, including nausea sometimes apanied by vomiting, constipation, anorexia, diarrhea and dyspepsia; CNSplaints, including somnolence, dry mouth, nervousness, insomnia, dizziness, tremor and agitation; and asthenia. Abnormal mostly delayed ejaculation was frequently reported by patients with obsessivepulsive disorder, primarily at doses over 150 mg/day. Adverse Events Leading to Discontinuation of Treatment: Fifteen percent of approximately 25000 patients who received fluvoxamine in clinical trials discontinued treatment due to an adverse event. The moremon events causing discontinuation from depression trials included nausea and vomiting, insomnia, agitation, headache, abdominal pain, somnolence, dizziness, asthenia and anorexia. The mostmon events causing discontinuation in patients suffering from obsessivepulsive disorder included insomnia, asthenia and somnolence. Incidence of Adverse Experiences: Adverse events with an incidence of >= 5% reported in double-blind, placebo-controlled clinical trials in depression and in obsessivepulsive disorder are presented in table I for each indication. -------------------------------------------------------------------------- Table I Treatment - Emergent Adverse Experience Incidence >= 5% in Placebo-Controlled Clinical Trials for Depression and Obsessivepulsive Disorder* -------------------------------------------------------------------------- Percentage of Patients Reporting Event Depression OCD Body System/ Fluvoxamine Placebo Fluvoxamine Placebo Adverse Event N=222 N=192 N=160 N=160 ---------------------------------------------------------------------- Nervous System Somnolence 26.2 9.0 26.9 9.4 Agitation 15.7 8.9 3.8 0 Insomnia 14.4 10.4 31.3 15.0 Dizziness 14.8 13.5 9.4 4.4 Tremor 10.8 4.7 8.1 0.6 Hypokinesia 8.1 3.6 - - Hyperkinesia 6.7 8.9 - - Depression 4.0 4.2 6.3 4.4 Nervousness 2.2 1.6 15.6 5.0 Anxiety 2.3 2.1 9.4 6.9 Libido decreased - - 7.5 1.9 Thinking abnormal - - 6.9 3.8 Digestive System Nausea 36.5 10.9 28.8 6.9 Dry mouth 25.7 23.9 11.9 3.1 Constipation 18.0 6.8 14.4 8.8 Anorexia 14.9 6.3 5.0 3.1 Diarrhea 5.9 6.3 11.9 8.8 Dyspepsia 3.2 0 13.8 9.4 Body as a Whole Headache 21.6 18.7 20.0 23.8 Pain 5.9 3.7 4.4 1.3 Asthenia 4.9 3.2 28.8 9.4 Infection - - 11.3 9.4 Abdominal pain 3.6 3.6 5.6 8.1 Flu syndrome - - 5.0 3.8 Skin Sweating increased 11.2 12.5 6.9 1.9 Respiratory System Pharyngitis - - 6.3 5.0 Rhinitis 1.3 2.6 5.6 1.9 Special Senses Amodation abnormal 6.3 6.3 - - Taste perversion 3.2 3.1 5.0 0 Urogenital Urinary frequency 2.2 1.6 5.0 1.3 Abnormal ejaculation 1.4 0 17.9+ 0 --------------------------------------------------------------------- *Dosage titration at study initiation varied between the depression an d OCD trials. In depression, fluvoxamine was administered: Day 1, 50 mg hs; Day 2, 100 mg; Day 3, 150 mg then titrated to response. In OCD, fluvoxamine was administered: Days 1 to 4, 50 mg; Days 5 to 8, 100 mg, Days 9 to 14, 150 mg then titrated to response. +Corrected for gender males: n=78. --------------------------------------------------------------------- During premarketing and postmarketing studies, multiple doses of fluvoxamine were administered to approximately 25000 patients. All events with an incidence of > 0.01% are listed, regardless of relation to drug, except those in terms so general as to be uninformative. Events are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: Frequent occurring on 1 or more occasions in at least 1% of patients, infrequent occurring in less than 1%, but at least 0.1% of patients, or rare occurring in less than 0.1% but at least in 0.01% of patients. Multiple events may have been reported by a single patient. It is important to emphasize that although the events reported did occur during treatment with fluvoxamine, they were not necessarily caused by it. Nervous System: Frequent: Somnolence, dry mouth, insomnia, dizziness, nervousness, tremor, vertigo, thinking abnormal, agitation, anxiety, amnesia, depression. Infrequent: Abnormal dreams, paresthesia, vasodilatation, libido decreased, depersonalization, psychotic depression, hypertonia, confusion, apathy, emotional lability, ataxia, abnormal gait, hostility, hyperkinesia, libido increased, hypokinesia, euphoria, neurosis, incoordination, hypesthesia, increased salivation. Rare: Screaming syndrome, hypotonia, hemiplegia, hallucinations, akathisia, manic reaction, myoclonus, twitching, drug dependence, stupor, delirium, convulsion, neuralgia, dysarthria, paranoid reaction, extrapyramidal syndrome, neuropathy, CNS neoplasia, akinesia, dyskinesia, paralysis, psychosis, CNS stimulation,a, delusions, hyperesthesia, hysteria, schizophrenic reaction, torticollis, trismus, dystonia, reflexes decreased. Digestive: Frequent: Nausea, vomiting, dyspepsia, constipation, diarrhea, anorexia. Infrequent: Flatulence, dysphagia, increased appetite, eructation, thirst, colitis. Rare: Gastroenteritis, gastritis, stomatitis, glossitis, hepatitis, esophagitis, fecal incontinence, gingivitis, jaundice, mouth ulceration, rectal hemorrhage, melena, tongue discoloration, tooth disorder, biliary pain, gastrointestinal carcinoma, gastrointestinal hemorrhage, hematemesis, liver function tests abnormal, tenesmus, tongue edema. Cardiovascular: Frequent: Palpitation. Infrequent: Syncope, tachycardia, postural hypotension, hypotension, migraine, hypertension. Rare: Angina pectoris, arrhythmia, myocardial infarct, pallor, bradycardia, extrasystoles, hemorrhage, peripheral vascular disorder, cerebrovascular accident, shock. Body as a Whole: Frequent: Asthenia, headache, abdominal pain, malaise, pain. Infrequent: Back pain, chills, chest pain, suicide attempt, fever, neck pain, infection, allergic reaction, accidental injury, flu syndrome. Rare: Overdose, face edema, hangover effect, abdomen enlarged, halitosis, neck rigidity, pelvic pain, hernia, chills and fever. Skin: Frequent: Sweating increased. Infrequent: Pruritus, rash. Rare: Urticaria, acne, eczema, dry skin, alopecia, psoriasis, furunculosis, Herpes simplex, Herpes zoster, maculopapular rash. Respiratory: Infrequent: Dyspnea, pharyngitis, rhinitis. Rare: Cough increased, yawn, epistaxis, hyperventilation, sinusitis, bronchitis, laryngismus, hiccup, pneumonia, asthma, laryngitis, voice alternation. Special Senses: Infrequent: Taste perversion, tinnitus, amblyopia, abnormal vision, hyperacusis. Rare: Conjunctivitis, abnormality of amodation, taste loss, eye pain, lacrimation disorder, diplopia, dry eyes, mydriasis, ear pain, parosmia, deafness, photophobia, blepharitis. Musculoskeletal: Infrequent: Myalgia, arthralgia, myasthenia, tetany. Rare: Leg cramps, arthrosis, rheumatoid arthritis, arthritis, bone pain, pathological fracture. Urogenital: Infrequent: Urinary frequency, impotence, dysuria, metrorrhagia, abnormal ejaculation. Rare: Urinary incontinence, breast pain, urinary retention, urinary urgency, cystitis, nocturia, menorrhagia, anorgasmia, female lactation, vaginitis, amenorrhea, dysmenorrhea, urinary tract infection, hematuria, kidney pain, prostatic disorder, polyuria, leukorrhea. Metabolic and Nutritional: Frequent: Weight gain. Infrequent: Weight loss, peripheral edema. Rare: Alcohol intolerance, dehydration, obesity, edema. Hematic and Lymph: Rare: Ecchymosis, cyanosis, anemia, lymphadenopathy, thrombocytopenia. Overdose Symptoms: More than 300 cases of overdosage with fluvoxamine, alone or inbination with otherpounds, have been reported. The mostmon symptoms of overdosage include gastrointestinalplaints nausea, vomiting and diarrhea, somnolence and dizziness. Cardiac events tachycardia, bradycardia, hypotension, liver function disturbances, convulsions anda have also been reported. Among 300 patients reported to have taken deliberate overdoses of fluvoxamine, there have been 15 deaths, all but one of which occurred in patients who were confirmed to have taken multiple medications. Treatment: There is no specific antidote to fluvoxamine. In situations of overdosage, the stomach should be emptied as soon as possible after tablet ingestion and symptomatic treatment initiated. The repeated use of medicinal charcoal is also rmended. Due to the large distribution volume of fluvoxamine, forced diuresis or dialysis is unlikely to be of benefit. The highest documented dose of fluvoxamine ingested by a patient is 9000 mg; this patient recoveredpletely with symptomatic treatment only. Dosage Depression: Adult Dosage: Treatment should be initiated at the lowest possible dose 50 mg given once daily at bedtime, and then increased to 100 mg daily at bedtime after a few days, as tolerated. The effective daily dose usually lies between 100 and 200 mg, and should be adjusted gradually according to the individual response of the patient, up to a maximum of 300 mg. Dosage increases should be made in 50 mg increments. Doses above 150 mg should be divided so that a maximum of 150 mg is given in the bedtime dose. Tablets should be swallowed with water and without chewing. Obsessivepulsive Disorder: Adult Dosage: Treatment should be initiated at the lowest possible dose 50 mg given once daily at bedtime, and then increased to 100 mg daily at bedtime after a few days, as tolerated. The effective daily dose usually lies between 100 and 300 mg, and should be adjusted gradually according to the individual response of the patient, up to a maximum of 300 mg. If no improvement is observed within 10 weeks, treatment with fluvoxamine should be reconsidered. Dosage increases should be made in 50 mg increments. Doses above 150 mg should be divided so that a maximum of 150 mg is given in the bedtime dose. Fluvoxamine should be swallowed with water and without chewing. Hepatic or Renal Insufficiency: Patients with hepatic or renal insufficiency should begin treatment with a low dose and be carefully monitored. Children: The safety and effectiveness of fluvoxamine in children under 18 years of age have not been established. Geriatrics: Since there is limited clinical experience in the geriatric age group, caution is rmended when administering fluvoxamine to elderly patients. luvox weight loss reviews_6 Dosage Use:luvox weight loss reviews_6 The doctor can recommend a change in dosage. luvox weight loss reviews_6 is taken according to the intensity of the problem as well as the preceding medical history. luvox weight loss reviews_6 treatment has to be taken on its own under a doctor supervision. It can cause a reaction if used with certain drugs. luvox weight loss reviews_6 patients should not go vaccinations when they are using this drug. It can affect the effectiveness of the vaccine making it weak. Health experts say that all patients under luvox weight loss reviews_6 should wear a medical tag to show that they are using it. It can help in case one has to be attended to in an emergency room when one is unconscious.
luvox weight loss reviews_6 is not the cure straight away. The situation has to be evaluated by a professional medic. This will give a diagnosis on the course and the right treatment. There are some conditions that prevent one from using luvox weight loss reviews_6.

When Not To Use luvox weight loss reviews_6: When one is breastfeeding, it is wrong to use the luvox weight loss reviews_6. There are other alternative drugs for allergy that an expectant mother can use. This can drug can only be used in case of an emergency. luvox weight loss reviews_6 is dangerous especially in the first trimester.
A nursing mother should not use this drug. If this happens, the baby will be taking the luvox weight loss reviews_6 through breast milk at very high doses. This can affect the baby immunity. It is not healthy at all to use luvox weight loss reviews_6 when breastfeeding.

Hepatic Enzymes: Treatment with fluvoxamine has been rarely associated with increases in hepatic enzymes, usually apanied by symptoms. Fluvoxamine administration should be discontinued in such cases.bination with Alcohol: Fluvoxamine may potentiate the effects of alcohol and increase the level of psychomotor impairment. Occupational Hazards: Sedation may occur in some patients. Therefore, patients should be cautioned about participating in activities requiringplete mental alertness, judgment and physical coordination - such as driving an automobile or performing hazardous tasks - until they are reasonably certain that treatment with fluvoxamine does not affect them adversely. Suicide: The possibility of a suicide attempt is inherent in depression and may persist until significant remission occurs. Therefore, high-risk patients should be closely supervised throughout therapy and consideration should be given to the possible need for hospitalization. In order to minimize the opportunity for overdosage, prescriptions for fluvoxamine should be written for the smallest quantity of drug consistent with good patient management. Coitant Illness: Fluvoxamine has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were systematically excluded from premarketing clinical studies. Pregnancy and Lactation: Safe use of fluvoxamine during pregnancy and lactation has not been established. Therefore, it should not be administered to women of childbearing potential or nursing mothers unless, in the opinion of the treating physician, the expected benefits to the patient outweigh the possible hazards to the child or fetus. Children: Safety and efficacy in children under 18 years of age have not been established. Drug Interactions:bined use of fluvoxamine and MAO inhibitors is contraindicated see Contraindications. An increase in tricyclic antidepressant blood levels has also been reported in patients taking fluvoxamine coitantly. Lithium, and possibly tryptophan, may enhance the serotonergic effects of fluvoxamine; thesebinations should therefore be used with caution. Fluvoxamine may prolong the elimination of drugs which are metabolized by oxidation in the liver, and a clinically significant interaction is more likely when the second agent has a narrow therapeutic index, as is the case with warfarin, phenytoin and theophylline. Suchbinations should therefore be administered with caution, and consideration be given to lowering the dose of the second agent. In interaction studies, a 5-fold increase in plasma levels of propranolol and a 65% increase in warfarin plasma levels were seen during concurrent administration of fluvoxamine. An absence of pharmacokinetic interaction has been seen with digoxin and atenolol, which are not significantly metabolized in the liver. Cytochrome P450 Isozyme IID6: Like other selective serotonin reuptake inhibitors, fluvoxamine inhibits the specific hepatic cytochrome P450 isozyme IID6 which is responsible for the metabolism of debrisoquine and sparteine. Although the clinical significance of this effect has not been established, inhibition of IID6 may lead to elevated plasma levels of co-administered drugs which are metabolized by this isozyme. Drugs metabolized by cytochrome P450IID6 include the tricyclic antidepressants e.g. nortriptyline, amitriptyline, imipramine, and desipramine, phenothiazine neuroleptics e.g. perphenazine and thioridazine, and Type 1C antiarrhythmics e.g. propafenone and flecainide. Adverse Effectsmonly Observed: In clinical trials, the mostmonly observed adverse events associated with fluvoxamine administration, and not seen at an equivalent incidence among placebo-treated patients, were gastrointestinalplaints, including nausea sometimes apanied by vomiting, constipation, anorexia, diarrhea and dyspepsia; CNSplaints, including somnolence, dry mouth, nervousness, insomnia, dizziness, tremor and agitation; and asthenia. Abnormal mostly delayed ejaculation was frequently reported by patients with obsessivepulsive disorder, primarily at doses over 150 mg/day. Adverse Events Leading to Discontinuation of Treatment: Fifteen percent of approximately 25000 patients who received fluvoxamine in clinical trials discontinued treatment due to an adverse event. The moremon events causing discontinuation from depression trials included nausea and vomiting, insomnia, agitation, headache, abdominal pain, somnolence, dizziness, asthenia and anorexia. The mostmon events causing discontinuation in patients suffering from obsessivepulsive disorder included insomnia, asthenia and somnolence. Incidence of Adverse Experiences: Adverse events with an incidence of >= 5% reported in double-blind, placebo-controlled clinical trials in depression and in obsessivepulsive disorder are presented in table I for each indication. -------------------------------------------------------------------------- Table I Treatment - Emergent Adverse Experience Incidence >= 5% in Placebo-Controlled Clinical Trials for Depression and Obsessivepulsive Disorder* -------------------------------------------------------------------------- Percentage of Patients Reporting Event Depression OCD Body System/ Fluvoxamine Placebo Fluvoxamine Placebo Adverse Event N=222 N=192 N=160 N=160 ---------------------------------------------------------------------- Nervous System Somnolence 26.2 9.0 26.9 9.4 Agitation 15.7 8.9 3.8 0 Insomnia 14.4 10.4 31.3 15.0 Dizziness 14.8 13.5 9.4 4.4 Tremor 10.8 4.7 8.1 0.6 Hypokinesia 8.1 3.6 - - Hyperkinesia 6.7 8.9 - - Depression 4.0 4.2 6.3 4.4 Nervousness 2.2 1.6 15.6 5.0 Anxiety 2.3 2.1 9.4 6.9 Libido decreased - - 7.5 1.9 Thinking abnormal - - 6.9 3.8 Digestive System Nausea 36.5 10.9 28.8 6.9 Dry mouth 25.7 23.9 11.9 3.1 Constipation 18.0 6.8 14.4 8.8 Anorexia 14.9 6.3 5.0 3.1 Diarrhea 5.9 6.3 11.9 8.8 Dyspepsia 3.2 0 13.8 9.4 Body as a Whole Headache 21.6 18.7 20.0 23.8 Pain 5.9 3.7 4.4 1.3 Asthenia 4.9 3.2 28.8 9.4 Infection - - 11.3 9.4 Abdominal pain 3.6 3.6 5.6 8.1 Flu syndrome - - 5.0 3.8 Skin Sweating increased 11.2 12.5 6.9 1.9 Respiratory System Pharyngitis - - 6.3 5.0 Rhinitis 1.3 2.6 5.6 1.9 Special Senses Amodation abnormal 6.3 6.3 - - Taste perversion 3.2 3.1 5.0 0 Urogenital Urinary frequency 2.2 1.6 5.0 1.3 Abnormal ejaculation 1.4 0 17.9+ 0 --------------------------------------------------------------------- *Dosage titration at study initiation varied between the depression an d OCD trials. In depression, fluvoxamine was administered: Day 1, 50 mg hs; Day 2, 100 mg; Day 3, 150 mg then titrated to response. In OCD, fluvoxamine was administered: Days 1 to 4, 50 mg; Days 5 to 8, 100 mg, Days 9 to 14, 150 mg then titrated to response. +Corrected for gender males: n=78. --------------------------------------------------------------------- During premarketing and postmarketing studies, multiple doses of fluvoxamine were administered to approximately 25000 patients. All events with an incidence of > 0.01% are listed, regardless of relation to drug, except those in terms so general as to be uninformative. Events are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: Frequent occurring on 1 or more occasions in at least 1% of patients, infrequent occurring in less than 1%, but at least 0.1% of patients, or rare occurring in less than 0.1% but at least in 0.01% of patients. Multiple events may have been reported by a single patient. It is important to emphasize that although the events reported did occur during treatment with fluvoxamine, they were not necessarily caused by it. Nervous System: Frequent: Somnolence, dry mouth, insomnia, dizziness, nervousness, tremor, vertigo, thinking abnormal, agitation, anxiety, amnesia, depression. Infrequent: Abnormal dreams, paresthesia, vasodilatation, libido decreased, depersonalization, psychotic depression, hypertonia, confusion, apathy, emotional lability, ataxia, abnormal gait, hostility, hyperkinesia, libido increased, hypokinesia, euphoria, neurosis, incoordination, hypesthesia, increased salivation. Rare: Screaming syndrome, hypotonia, hemiplegia, hallucinations, akathisia, manic reaction, myoclonus, twitching, drug dependence, stupor, delirium, convulsion, neuralgia, dysarthria, paranoid reaction, extrapyramidal syndrome, neuropathy, CNS neoplasia, akinesia, dyskinesia, paralysis, psychosis, CNS stimulation,a, delusions, hyperesthesia, hysteria, schizophrenic reaction, torticollis, trismus, dystonia, reflexes decreased. Digestive: Frequent: Nausea, vomiting, dyspepsia, constipation, diarrhea, anorexia. Infrequent: Flatulence, dysphagia, increased appetite, eructation, thirst, colitis. Rare: Gastroenteritis, gastritis, stomatitis, glossitis, hepatitis, esophagitis, fecal incontinence, gingivitis, jaundice, mouth ulceration, rectal hemorrhage, melena, tongue discoloration, tooth disorder, biliary pain, gastrointestinal carcinoma, gastrointestinal hemorrhage, hematemesis, liver function tests abnormal, tenesmus, tongue edema. Cardiovascular: Frequent: Palpitation. Infrequent: Syncope, tachycardia, postural hypotension, hypotension, migraine, hypertension. Rare: Angina pectoris, arrhythmia, myocardial infarct, pallor, bradycardia, extrasystoles, hemorrhage, peripheral vascular disorder, cerebrovascular accident, shock. Body as a Whole: Frequent: Asthenia, headache, abdominal pain, malaise, pain. Infrequent: Back pain, chills, chest pain, suicide attempt, fever, neck pain, infection, allergic reaction, accidental injury, flu syndrome. Rare: Overdose, face edema, hangover effect, abdomen enlarged, halitosis, neck rigidity, pelvic pain, hernia, chills and fever. Skin: Frequent: Sweating increased. Infrequent: Pruritus, rash. Rare: Urticaria, acne, eczema, dry skin, alopecia, psoriasis, furunculosis, Herpes simplex, Herpes zoster, maculopapular rash. Respiratory: Infrequent: Dyspnea, pharyngitis, rhinitis. Rare: Cough increased, yawn, epistaxis, hyperventilation, sinusitis, bronchitis, laryngismus, hiccup, pneumonia, asthma, laryngitis, voice alternation. Special Senses: Infrequent: Taste perversion, tinnitus, amblyopia, abnormal vision, hyperacusis. Rare: Conjunctivitis, abnormality of amodation, taste loss, eye pain, lacrimation disorder, diplopia, dry eyes, mydriasis, ear pain, parosmia, deafness, photophobia, blepharitis. Musculoskeletal: Infrequent: Myalgia, arthralgia, myasthenia, tetany. Rare: Leg cramps, arthrosis, rheumatoid arthritis, arthritis, bone pain, pathological fracture. Urogenital: Infrequent: Urinary frequency, impotence, dysuria, metrorrhagia, abnormal ejaculation. Rare: Urinary incontinence, breast pain, urinary retention, urinary urgency, cystitis, nocturia, menorrhagia, anorgasmia, female lactation, vaginitis, amenorrhea, dysmenorrhea, urinary tract infection, hematuria, kidney pain, prostatic disorder, polyuria, leukorrhea. Metabolic and Nutritional: Frequent: Weight gain. Infrequent: Weight loss, peripheral edema. Rare: Alcohol intolerance, dehydration, obesity, edema. Hematic and Lymph: Rare: Ecchymosis, cyanosis, anemia, lymphadenopathy, thrombocytopenia. Overdose Symptoms: More than 300 cases of overdosage with fluvoxamine, alone or inbination with otherpounds, have been reported. The mostmon symptoms of overdosage include gastrointestinalplaints nausea, vomiting and diarrhea, somnolence and dizziness. Cardiac events tachycardia, bradycardia, hypotension, liver function disturbances, convulsions anda have also been reported. Among 300 patients reported to have taken deliberate overdoses of fluvoxamine, there have been 15 deaths, all but one of which occurred in patients who were confirmed to have taken multiple medications. Treatment: There is no specific antidote to fluvoxamine. In situations of overdosage, the stomach should be emptied as soon as possible after tablet ingestion and symptomatic treatment initiated. The repeated use of medicinal charcoal is also rmended. Due to the large distribution volume of fluvoxamine, forced diuresis or dialysis is unlikely to be of benefit. The highest documented dose of fluvoxamine ingested by a patient is 9000 mg; this patient recoveredpletely with symptomatic treatment only. Dosage Depression: Adult Dosage: Treatment should be initiated at the lowest possible dose 50 mg given once daily at bedtime, and then increased to 100 mg daily at bedtime after a few days, as tolerated. The effective daily dose usually lies between 100 and 200 mg, and should be adjusted gradually according to the individual response of the patient, up to a maximum of 300 mg. Dosage increases should be made in 50 mg increments. Doses above 150 mg should be divided so that a maximum of 150 mg is given in the bedtime dose. Tablets should be swallowed with water and without chewing. Obsessivepulsive Disorder: Adult Dosage: Treatment should be initiated at the lowest possible dose 50 mg given once daily at bedtime, and then increased to 100 mg daily at bedtime after a few days, as tolerated. The effective daily dose usually lies between 100 and 300 mg, and should be adjusted gradually according to the individual response of the patient, up to a maximum of 300 mg. If no improvement is observed within 10 weeks, treatment with fluvoxamine should be reconsidered. Dosage increases should be made in 50 mg increments. Doses above 150 mg should be divided so that a maximum of 150 mg is given in the bedtime dose. Fluvoxamine should be swallowed with water and without chewing. Hepatic or Renal Insufficiency: Patients with hepatic or renal insufficiency should begin treatment with a low dose and be carefully monitored. Children: The safety and effectiveness of fluvoxamine in children under 18 years of age have not been established. Geriatrics: Since there is limited clinical experience in the geriatric age group, caution is rmended when administering fluvoxamine to elderly patients. Administration Of The Drug luvox weight loss reviews_6:This drug should only be used if a doctor finds it necessary and healthy to prescribe. luvox weight loss reviews_6 should not be bought over the counter. luvox weight loss reviews_6 is a drug that poses some health risks. Given that it is an effective treatment one has to seek a professional opinion first. One has to follow the dosage luvox weight loss reviews_6 instruction accordingly. There are tablets as well as luvox weight loss reviews_6 tablets.

Click Buy luvox weight loss reviews_6 Online